On 3/30/2017, Shares of Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) closed at $0.5585 in last trading day. After noting the initial trading entry at $0.5976, it reached to a day’s high of $0.6050 and moved to a day’s low of $0.5500. The recent daily volume was 543.35 thousand as contrast to it’s an average volume of 1.02 million.
The last close of the Navidea Biopharmaceuticals, Inc. stock reflects that it traded up +0.3466% from its 50-day moving average of $0.5566. The stock traded below -21.3380% to its 200-day MA of $0.7100. Furthermore, it moved lower -63.0132% from its 52-week high of $1.5100 and +114.6426% up from $0.2602, which is 52-week low of the stock.
Navidea Biopharmaceuticals, Inc’s (NAVB) moved with shift of -2.02% in the past week. Over the last three months, the shares of the company have changed -17.87% and performed -41.82% over the last six months. The stock currently has Monthly Volatility of 12.26% and Weekly Volatility of 5.26%.
March 30, 2017 Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) reported business and financial highlights for the fourth quarter and year ended December 31, 2016.
2016 Top Highlights
Achieved $1 million in Lymphoseek® (technetium Tc 99m tilmanocept) injection commercial milestones upon sale of 100,000th patient dose and receipt of European approval to manufacture a reduced-mass vial
Completed sale of Lymphoseek to Cardinal Health 414, LLC (“Cardinal Health 414”) and received approximately $83 million in upfront payments including an advance of $3 million of future earnout payments, with up to $227 million in potential additional earnout payments through 2026
Initiated intravenous (“IV”) dose escalation Phase 1 imaging/disease-finding study in rheumatoid arthritis (“RA”) of ten cohorts with three dose cohorts completed with major escalations and imaging of active RA
Completed nine-subject cardiovascular imaging disease-finding study in HIV/CV patients and published clinical results in The Journal of Infectious Diseases
Awarded $1.8 million Fast-track Small Business Innovation Research (“SBIR”) Grant for Manocept™-based treatment for Kaposi’s Sarcoma (“KS”)
Appointed Michael M. Goldberg, M.D., as President and Chief Executive Officer and Eric K. Rowinsky, M.D., as Chairman of the Board of Directors
Anworth Mortgage Asset Corporation (NYSE:ANH) finalized the last transaction at value of $5.49, with a daily change of -0.18% or -0.01 points. The company maintained volume of 519.98 thousand shares. In past trading day, the stock hit the maximum price of $5.51 and touched to minimum value of $5.46. It has a market cap of $ 525.78M.
As of last trade close, the stock is trading downside -1.26% from its one year high of $5.56 and moved +22.82% upward from $4.47, which is one year low of the stock.
The stock traded above +1.34% from its 50-day moving average of $5.42. Furthermore, the stock moved up +6.08% to its 200-day MA of $ 5.18.
During the last month, Anworth Mortgage Asset Corporation’s (ANH) has changed 2.98% and performed 16.82% over the last 6 months. The mean rating score for this stock is at 3.00. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 1.51% in recent month and observed Weekly Volatility of 1.40%.
Anworth Mortgage Asset Corporation operates as a real estate investment trust primarily in the United States. It invests in, finances, and manages leveraged portfolio of residential mortgage-backed securities that are guaranteed by government-sponsored enterprises, such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation. The company also invests in non-agency mortgage investments that are guaranteed by private institutions, such as commercial banks; and other mortgage-related investments consisting of mortgage derivative securities, mortgage warehouse participations, and subordinated interests, as well as in mortgage loans and other investments. It qualifies as a real estate investment trust for federal income tax purposes. The company generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. Anworth Mortgage Asset Corporation was founded in 1997 and is headquartered in Santa Monica, California.